All In Biotech

Drug Trial Radar · NCT06474455

A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

A Phase IB/II, Open-Label, Multicentre Clinical Study to Evaluate the Safety, Tolerability and Efficacy of SHR-9839 for Injection in Combination With Other Therapies in Patients With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 156 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

156

Planned (sponsor's estimate)

Start

Jul 2, 2024

Primary completion

Jun 2029

Study completion Dec 2029

Sponsor

Sponsor type
Industry
First posted
Jun 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is an open-label, multicenter Phase IB/II clinical trial to evaluate the safety, tolerability and efficacy of SHR-9839 for injection in combination with other antitumor therapies in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumors

Interventions

  • SHR-9839 for InjectionDrug

    SHR-9839 for injection.

  • SHR-A1921 for InjectionDrug

    SHR-A1921 for injection.

  • SHR-A2009 for InjectionDrug

    SHR-A2009 for injection.

  • Almonertinib Mesilate TabletsDrug

    Almonertinib Mesilate Tablets.

  • Pemetrexed Disodium for InjectionDrug

    Pemetrexed Disodium for Injection.

  • Carboplatin for injectionDrug

    Carboplatin for injection.

  • Paclitaxel injectionDrug

    Paclitaxel injection.

  • SHR-1316 InjectionDrug

    SHR-1316 injection.

  • SHR-9839 for Injection (sc)Drug

    SHR-9839 for Injection (sc).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicity (DLT) (phase IB)Time frame: 21 days after the first dose was administered to each subject, up to approximately 24 months.
  2. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) and laboratory abnormalities (phase IB)Time frame: Begin from sign the ICF until the end of the safety follow-up period, up to approximately 24 months.
  3. Objective Response Rate (ORR) (phase II).Time frame: The first treatment lasted until disease progression, up to approximately 24 months.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Henan Cancer Hospital

    Zhengzhou, Henan, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.